Posts tagged homozygous
HCW starts Gemphire at buy

H.C. Wainwright launched coverage of Gemphire Therapeutics (NASDAQ:GEMP) with a “buy” rating and a price target of $21, saying it views the sell off in the shares following results of the ROYAL-1 clinical trial as overdone. The stock closed at $9.17 on August 30.

Read More
Stifel downgrades Nivalis to hold

Stifel downgraded Nivalis Therapeutics (NASDAQ:NVLS) to “ hold” from “buy” and slashed its price target to $3.25 from $16 after the company released Phase 2 data for cavosonstat in the treatment of patients with homozygous F508del CF that were stably on Orkambi. The stock closed at $6.25 on Monday.

Read More
Roth resumes coverage of CymaBay

Roth Capital Partners has resumed coverage of CymaBay Therapeutics (NASDAQ:CBAY) with a “buy” rating and $4 price target. The stock closed at $1.57 on Friday.

“In our opinion, while catalysts for the next 12-to-18 months are limited, the potential partnering of arhalofenate could be a significant driver for the shares, enhancing CymaBay’s coffers, validating the company’s approach, bridging the catalyst gap until additional data can be gleaned from MBX-8025’s HoFH and PBC programs, and increasing confidence in management’s execution,” writes analyst Sa’ar Yaniv.

Read More
QLT and Aegerion Pharma to merge

QLT (NASDAQ:QLTI; TSX:QLT) and Aegerion Pharmaceuticals (NASDAQ:AEGR) have entered into a definitive merger agreement, with the resulting company to be renamed, Novelion Therapeutics.

Under the accord, each outstanding share of Aegerion common stock will be exchanged for 1.0256 shares of QLT common stock.

Read More